Adia Nutrition Strikes Major Partnership with Leading Atlanta Clinic to Launch Groundbreaking Autism Clinical Study

Rhea-AI Summary

Adia Nutrition (OTCQB: ADIA) announced a strategic partnership with a leading Atlanta clinic to supply regenerative products for a new Autism Spectrum Disorder clinical study. The trial will enroll 100 participants, each receiving 3 infusions of AdiaVita (total 300 infusions); a single infusion is noted at about $8,000 as a price benchmark. Adia Med of Winter Park is separately recruiting for its own autism study starting May 2026. Adia Labs products are limited to research or IRB-approved studies and meet stated FDA quality and donor standards.

Positive

• Exclusive supplier role for Atlanta clinic study
• Study size: 100 participants, 300 total infusions
• Adia Med study beginning May 2026
• Products tested to meet stated FDA quality and donor standards

Negative

• Treatments limited to research/IRB-approved studies, not approved therapies
• High cost benchmark: about $8,000 per single infusion
• No efficacy data yet from the announced Atlanta study

News Market Reaction – ADIA

+23.89%

+23.89% Session close to close

In the Apr 8 session, ADIA gained 23.89%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Winter Park, Florida--(Newsfile Corp. - April 8, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, today announced a strategic partnership with a prominent clinic in Atlanta, Georgia. Adia Labs will serve as the exclusive supplier of regenerative products for the clinic's new Autism Spectrum Disorder (ASD) clinical study. This partnership is a key part of Adia Nutrition's 2026 plan to build solid scientific evidence for regenerative therapies that have the potential to change lives.

"We are thrilled to partner with this forward-thinking Atlanta clinic while Adia Med of Winter Park continues recruiting for its own autism study," said Larry Powalisz, CEO of Adia Nutrition, Inc. "This collaboration is a major milestone for regenerative medicine in autism." "Our end goal with these Autism studies is to ultimately demonstrate that our Autism protocols are viable treatments that must be insurable by both private insurers and government insurers like Medicare and Medicaid."

The Atlanta study will test AdiaVita, a product derived from umbilical cord blood that is rich in stem cells and exosomes. The study will include 100 participants, each receiving 3 infusions of AdiaVita, comprising a total of 300 AdiaVita infusions. To put this in perspective, patients receiving a single infusion at Adia Med of Winter Park typically pay $8000 per infusion. Researchers will examine whether it can help the body repair itself, lower inflammation, and lead to real improvements for people with autism.

Autism affects about 1 in 31 children in the United States (roughly 3.2%), according to the latest CDC data. This rate has risen sharply over the past 20 years. The financial burden is huge. Autism costs the U.S. between $236 billion and $262 billion every year in medical care, support services, and lost productivity.

The Adia Med Autism study is important because it will add strong clinical data on the use of stem cells for autism. It is also a clear step toward the goal of future insurance coverage, which would make these treatments more affordable and available to more families.

Adia Med of Winter Park is actively recruiting participants for its own dedicated autism study, which begins in May 2026. These two efforts together show Adia Nutrition's serious push to advance multiple approved research programs this year.

Adia Labs products are used only for research or Institutional Review Board (IRB)-approved studies. They are carefully tested and meet strict FDA quality and donor standards.

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/291541

FAQ

What is the design and size of the Atlanta autism study involving ADIA?

The Atlanta study will enroll 100 participants, each receiving 3 infusions for a total of 300 infusions. According to the company, the trial will test AdiaVita derived from umbilical cord blood to assess inflammation and functional changes.

When does Adia Med's separate autism study for ADIA begin?

Adia Med of Winter Park begins recruiting for its autism study in May 2026. According to the company, this runs alongside the Atlanta partnership as part of Adia's 2026 clinical research plan.

What product will ADIA supply for the Atlanta clinical trial?

ADIA will supply AdiaVita, a product derived from umbilical cord blood rich in stem cells and exosomes. According to the company, AdiaVita is intended for use only in IRB-approved research studies.

How many AdiaVita infusions will each participant receive in the ADIA study?

Each participant will receive 3 infusions, with the study totaling 300 infusions across 100 participants. According to the company, researchers will monitor repair, inflammation, and clinical outcomes.

Does ADIA claim the autism treatments are covered by insurance now?

No, the company says the goal is to build evidence toward future insurance coverage, not that coverage exists now. According to the company, these studies aim to support potential private and public insurer consideration.

Are ADIA products approved for general clinical use outside research?

No, Adia Labs products are used only for research or IRB-approved studies and are not presented as approved therapies. According to the company, products meet stated FDA quality and donor standards for research use.